Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency.

Sas T, Mulder P, Hokken-Koelega A

The Journal of clinical endocrinology and metabolism1 Oct 2000Cited by 91 (Europe PMC)

PMID11061539DOI10.1210/jcem.85.10.6917PepBankPUB-11061539

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In short children born SGA, the 6-yr height SD-score increase was significantly higher with 6 IU/m2 x day (2.7) than 3 IU/m2 day (2.2).
In plain wordsIn short children born SGA, the higher GH dose increased height SD score more than the lower dose.
Peptide
HGH (somatotropin)
Outcome
IncreaseHeight SD score change
Study
n = 79
Comparator
3 IU/m2 day
Outcome group
Linear growth · Endocrine and hormones
Studied dose
6 IU/m2 x day · 6 yearsAs given in this study (human).
Measurements
6-yr increase in height SD-score
2.7 SD-score
6 IU/m2 x day group
6-yr increase in height SD-score
2.2 SD-score
3 IU/m2 day group
Source sentences
Summary
Although the mean 6-yr increase in height SD-score was significantly higher in the children receiving GH treatment with 6 IU/m2 x day (2.7) than in those receiving treatment with 3 IU/m2 day (2.2),
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153905
02HumanRandomized controlled trialEfficacy outcome
In short children born SGA, changes in BMI, skinfolds, blood pressure and lipids did not differ between GH dosage groups.
In plain wordsIn short children born SGA, changes in BMI, skinfolds, blood pressure and lipids did not differ between GH doses.
Peptide
HGH (somatotropin)
Outcome
No significant changeDose comparison of BMI, skinfolds, blood pressure and lipids
Study
n = 79
Comparator
Other GH dosage group
Outcome group
Body composition · Metabolic and weight
Studied dose
3 or 6 IU/m2 body surface/day · 6 yearsAs given in this study (human).
Source sentences
Summary
no differences in the changes in BMI, skinfold measurements, BP, and lipids were found between the GH dosage groups.
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153906
03HumanNon-randomized trialEfficacy outcome
In short children born SGA, subcutaneous fat showed no overall change during GH treatment compared with age-matched references.
In plain wordsIn short children born SGA, subcutaneous fat showed no overall change compared with age-matched references during GH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSubcutaneous fat
Study
n = 79
Comparator
Age-matched references
Outcome group
Body composition · Metabolic and weight
Studied dose
3 or 6 IU/m2 body surface/day · 6 yearsAs given in this study (human).
Source sentences
Summary
During long-term continuous GH treatment, the BMI normalized without overall changes in sc fat compared with age-matched references, whereas the BP SD-score and the atherogenic index decreased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153902
04HumanNon-randomized trialEfficacy outcome
In short children born SGA, blood pressure SD score decreased significantly during GH treatment.
In plain wordsIn short children born SGA, blood pressure SD score decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseBlood pressure SD score
Study
n = 79
Outcome group
Blood pressure · Cardiovascular
Studied dose
3 or 6 IU/m2 body surface/day · 6 yearsAs given in this study (human).
Source sentences
Summary
During long-term continuous GH treatment, the BMI normalized without overall changes in sc fat compared with age-matched references, whereas the BP SD-score and the atherogenic index decreased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153903
05HumanNon-randomized trialEfficacy outcome
In short children born SGA, the atherogenic index decreased significantly during GH treatment.
In plain wordsIn short children born SGA, the atherogenic index decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseAtherogenic index
Study
n = 79
Outcome group
Lipids · Metabolic and weight
Studied dose
3 or 6 IU/m2 body surface/day · 6 yearsAs given in this study (human).
Source sentences
Summary
During long-term continuous GH treatment, the BMI normalized without overall changes in sc fat compared with age-matched references, whereas the BP SD-score and the atherogenic index decreased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153904
06HumanNon-randomized trialEfficacy outcome
In short children born SGA, BMI normalized during long-term GH treatment.
In plain wordsIn short children born SGA, BMI normalized during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseBMI normalization
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
3 or 6 IU/m2 body surface/day · 6 yearsAs given in this study (human).
Source sentences
Summary
During long-term continuous GH treatment, the BMI normalized without overall changes in sc fat compared with age-matched references, whereas the BP SD-score and the atherogenic index decreased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153901
07HumanObservational studyEfficacy outcome
In short children born SGA receiving GH, skinfold SD score decreased more in GH-deficient than non-GH-deficient children after 6 yr.
In plain wordsIn short children born SGA receiving GH, skinfold SD score decreased more in GH-deficient than non-GH-deficient children.
Peptide
HGH (somatotropin)
Outcome
DecreaseSkinfold SD score by GH deficiency
Study
n = 79
Comparator
Non-GH-deficient children receiving GH
Outcome group
Body composition · Metabolic and weight
Studied dose
3 or 6 IU/m2 body surface/day · 6 yearsAs given in this study (human).
Source sentences
Summary
but after 6 yr of GH treatment the skinfold SD-score and BP SD-score had decreased significantly more in the GHD than in the non-GHD children.
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153907
08HumanObservational studyEfficacy outcome
In short children born SGA receiving GH, blood pressure SD score decreased more in GH-deficient than non-GH-deficient children after 6 yr.
In plain wordsIn short children born SGA receiving GH, blood pressure SD score decreased more in GH-deficient than non-GH-deficient children.
Peptide
HGH (somatotropin)
Outcome
DecreaseBlood pressure SD score by GH deficiency
Study
n = 79
Comparator
Non-GH-deficient children receiving GH
Outcome group
Blood pressure · Cardiovascular
Studied dose
3 or 6 IU/m2 body surface/day · 6 yearsAs given in this study (human).
Source sentences
Summary
but after 6 yr of GH treatment the skinfold SD-score and BP SD-score had decreased significantly more in the GHD than in the non-GHD children.
2 context sentences(design, population, supporting numbers)
Summary · context
All children participated in a randomized, double-blind, dose-response multicenter GH trial.
Summary · context
Four- and 6-yr data were compared between two GH dosage groups (3 vs. 6 IU/m2 body surface/day).
Report a problemFND-1106153908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01697644

Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation

Novo Nordisk A/Sn = 75Oct 1990 to May 2005

Foetal Growth Problem · Small for Gestational Age

Trial page ClinicalTrials.govUpdated 18 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.